None of the Apoe −/− , Apoe −/− ; Prkaa1 −/− or Apoe −/− ; Prkaa2 −/− mice showed evidence of AAA when infused with vehicle ( Fig. 1a-d) . However, both low-dose (1 mg per kg of body weight per day) and high-dose (5 mg per kg of body weight per day) nicotine infusion for 6 weeks significantly increased the incidence of AAA, maximal aortic diameters and total aortic weights in Apoe −/− and Apoe −/− ; Prkaa1 −/− mice ( Fig. 1a-d and Supplementary Fig. 1a-c) . Compared to mice infused with vehicle, nicotine infusion markedly increased the size of the aortic lumen and the wall thickness of both Apoe −/− and Apoe −/− ; Prkaa1 −/− mice (Fig. 1e) .
Apoe −/− ; Prkaa2 −/− mice had a markedly reduced incidence of nicotine-induced AAA compared to Apoe −/− mice (Fig. 1b) . The maximal aortic diameter and total aortic weight in nicotine-infused Apoe −/− ; Prkaa2 −/− mice were also significantly less than those in nicotineinfused Apoe −/− mice (Fig. 1c,d) , and nicotine infusion did not cause significant elastic lamina degradation and aortic expansion in Apoe −/− ; Prkaa2 −/− mice (Fig. 1e,f) . VSMCs were the major cellular component in the area of the AAA, as shown by α-actin staining (Fig. 1e) . Taken together, these results indicate that deficiency of AMPK-α2 protects against nicotine-induced AAA formation in Apoe −/− mice in vivo.
AMPK-a2 deficiency attenuates AngII-induced AAA formation AAA induced by AngII infusion is a well-characterized mouse model of the disease 17, 18 . To further validate the role of AMPK-α2 in AAA, we examined the effects of a 4-week AngII infusion in Apoe −/− , Apoe −/− ; Prkaa1 −/− and Apoe −/− ; Prkaa2 −/− mice. As shown in Supplementary Tables 3 and 4, AngII infusion increased blood pressure but had no effects on heart rate or any metabolic indices. When infused with saline, there was no difference in the gross morphology of aortas among Apoe −/− , Apoe −/− ; Prkaa1 −/− and Apoe −/− ; Prkaa2 −/− mice ( Supplementary Fig. 2a) . Consistent with previous reports 3, 8, 19 , the incidence of AAA induced by AngII infusion in the present study was 85% and 80% in Apoe −/− and Apoe −/− ; Prkaa1 −/− mice, respectively ( Supplementary Fig. 2a,b) . Both the maximal abdominal aortic diameter ( Supplementary Fig. 2c ) and total aortic weight ( Supplementary  Fig. 2d ) were markedly higher in AngII-treated Apoe −/− and Apoe −/− ; Prkaa1 −/− mice compared to saline-treated control mice, consistent with previous reports [20] [21] [22] . Histological analysis showed that Apoe −/− and Apoe −/− ; Prkaa1 −/− mice infused with AngII had larger aortic lumens and increased aortic wall thickness ( Supplementary Fig. 2e ) compared to saline-treated control mice and that the elastic laminas in AngII-treated mice were frequently disrupted and degraded ( Supplementary Fig. 2f ).
In contrast, only 17% of AngII-infused Apoe −/− ; Prkaa2 −/− mice developed AAA (Supplementary Fig. 2b ). The maximal abdominal aortic diameter (Supplementary Fig. 2c ) and total aortic weight ( Supplementary Fig. 2d ) were markedly lower in AngII-treated Fig. 2e,f) . These results suggest that deficiency of AMPK-α2 reduces AngII-induced AAA formation in vivo.
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AMPK-a2 deficiency abolishes MMP2 upregulation in AAA mice
MMPs have a key role in the initiation and progression of AAA 23, 24 .
In particular, VSMC-derived MMP2 and macrophage-derived MMP9 are crucial for AAA formation 25, 26 . Thus, we next determined the relative contributions of MMP2 and MMP9 in nicotine-enhanced AAA formation. The expression of MMP2 was substantially increased in nicotine-infused Apoe −/− and Apoe −/− ; Prkaa1 −/− mice (Fig. 2a) . In contrast, Apoe −/− ; Prkaa2 −/− mice had reduced MMP2 protein expression after nicotine infusion (Fig. 2a) .
We next assessed MMP activity, mRNA levels and protein concentrations in isolated aortas from Apoe −/− , Apoe −/− ; Prkaa1 −/− and Apoe −/− ; Prkaa2 −/− mice. We were able to detect both MMP2 and MMP9 activity in all three groups of mice; however, MMP2 seemed to be the most predominant MMP in both vehicle-and nicotine-treated Apoe −/− , Apoe −/− ; Prkaa1 −/− and Apoe −/− ; Prkaa2 −/− mice (Fig. 2b) . Nicotine infusion increased MMP2 activity markedly in Apoe −/− and Apoe −/− ; Prkaa1 −/− mice and also did so to a lesser extent in Apoe −/− ; Prkaa2 −/− mice. Nicotine infusion had minimal effects on MMP9 activity in the three groups of mice. Moreover, nicotine infusion significantly increased MMP2 protein concentrations and MMP2 mRNA levels in Apoe −/− and Apoe −/− ; Prkaa1 −/− mice but not in Apoe −/− ; Prkaa2 −/− mice (Fig. 2c,d and Supplementary Fig. 3a) . Similarly, AngII infusion markedly increased the protein concentration and mRNA expression and activity of both MMP2 and MMP9 in Apoe −/− and Apoe −/− ; Prkaa1 −/− mice but not in Apoe −/− ; Prkaa2 −/− mice ( Supplementary Fig. 3b and 4a,b) . Prkaa1 and Supplementary Fig. 4c ). These data suggest that both AngII and nicotine trigger oxidative stress in vivo. Although ROS and inflammation are seen in Apoe −/− ; Prkaa2 −/− mice, these mice do not develop AAA because of an AMPK-α2 deficiency.
Vascular AMPK-a2 deficiency is essential for AAA inhibition Because AMPK-α1, rather than AMPK-α2, is the predominant AMPK isoform in macrophages and deletion of AMPK-α1 did not alter nicotine-or AngII-induced AAA formation, we reasoned that AMPK-α2 is likely acting in VSMCs to promote AAA formation.
To test this hypothesis, we performed reciprocal bone marrow transplants between Apoe −/− and Apoe −/− ; Prkaa2 −/− mice, in which bone marrow cells were transplanted into irradiated mice. After 42 d of engraftment, the transplanted mice were treated with nicotine (1 mg per kg of body weight per day for 42 days), which led to AAA formation in Apoe −/− mice transplanted with either Prkaa2 −/− or Prkaa2 +/+ bone marrow cells, with a similar incidence of approximately 20% (Fig. 3a) . However, AAA formation was not observed in Apoe −/− ; Prkaa2 −/− mice transplanted with either Prkaa2 −/− or Prkaa2 +/+ bone marrow cells (Fig. 3a) , and there was no difference in the maximum abdominal aortic diameter ( Fig. 3b) and total aortic weight ( Fig. 3c) between the two groups of mice. Similarly to nicotine infusion, AngII infusion caused AAA formation and increased AAA incidence ( Fig. 3d) , maximum abdominal aortic diameter ( Fig. 3e) and total aortic weight ( To obtain further support for the key role of VSMC-derived MMP2 in AAA formation, we acutely knocked down MMP2 expression using in vivo siRNA delivery. AngII or nicotine infusion increased pro-MMP2 protein concentrations in mice transfected with a control siRNA but not in mice transfected with the MMP2-targeted siRNA ( Supplementary Fig. 5a ). Accordingly, the amount of collagen IV, a direct substrate of MMP2, was reduced by AngII or nicotine infusion in control siRNA-transfected but not MMP2 siRNA-transfected mice ( Supplementary Fig. 5a ,b), and elastin degradation was also blocked in MMP2 siRNA-transfected mice ( Supplementary  Fig. 5b,c) . These results indicate that MMP2, rather than MMP9, mediates AngII-and nicotine-induced elastin degradation in the aortic wall.
AMPK activation increases pro-MMP2 expression in VSMCs
We next determined whether AMPK in VSMCs modulates MMP2 expression. Exposure of human VSMCs to low concentrations (0.01-0.1 µM) of nicotine, equivalent to the blood concentrations present in habitual smokers, led to AMPK activation ( Supplementary  Fig. 6a,b) . The degree of AMPK activation was similar to that caused by the potent AMPK activators 5-amino-4-imidazole carboxamide riboside (AICAR, 2 mM) or ONOO − (50 µM) ( Supplementary  Fig. 6a,b) . Nicotine treatment also increased the phosphorylation of AMPK-α at Thr172, which activates AMPK, in a timedependent manner (Supplementary Fig. 6c) . Likewise, treatment with AngII also caused phosphorylation of AMPK at Thr172. Treatment with AngII also resulted in phosphorylation of the AMPK substrate, acetyl-CoA carboxylase (ACC), at Ser79 in a time-dependent manner ( Supplementary Fig. 6d,e) , consistent with previously published data 13 .
We next tested the effects of nicotine or AngII on MMP2. Exposure of human VSMCs to AngII or nicotine markedly increased MMP2 mRNA and protein expression in whole-cell lysates and increased MMP2 activity in the culture medium ( Supplementary Fig. 3c,d  and 7a,b) . Compound C, an AMPK inhibitor, abolished the effects of AngII or nicotine on MMP2 (Supplementary Fig. 7a,b) , indicating that AMPK mediates MMP2 expression induced by AngII or nicotine. Transfection of the VSMCs with AMPK-α2 siRNA, but not AMPK-α1 siRNA, abolished the effects of nicotine, AngII, AICAR or metformin (an AMPK activator) on MMP2 protein and mRNA expression and MMP2 activity (Fig. 4a,b and Supplementary Fig. 3e,f) . Moreover, treatment of primary VSMCs isolated from wild-type (WT) or Prkaa1 −/− mice with AngII or nicotine upregulated MMP2 protein and mRNA expression and MMP2 activity, whereas treatment of VSMCs isolated from Prkaa2 −/− mice did not have these effects (Fig. 4c,d and Supplementary Fig. 3g,h ). Taken together, our results support the notion that AMPK-α2, but not AMPK-α1, is required for MMP2 expression in VSMCs.
MMP2 upregulation by nicotine or AngII is AP-2a dependent
The AP-2α transcription factor is required for MMP2 expression in endothelial cells 28 , and mice with knockdown of AP-2α die at birth as a result of abnormal neural, craniofacial and vascular development 29, 30 , suggesting a crucial role of AP-2α in regulating angiogenesis. We hypothesized that nicotine-or AngII-induced MMP2 upregulation is mediated by AP-2α. Transfection of VSMCs with AP-2α-specific or AMPK-α2-specific siRNAs, but not control siRNA, inhibited nicotine-induced pro-MMP2 protein expression and MMP2 activity (Fig. 5a) , implying that the upregulation of MMP2 by nicotine requires both AMPK-α2 and AP-2α. Similarly, transfection of VSMCs with AP-2α siRNA, but not control siRNA, abolished AngII-induced MMP2 upregulation (Fig. 5b) . Because AP-2α is required for nicotine-or AngII-induced MMP2 mRNA and protein expression, we reasoned that AngII and nicotine might activate AP-2α to increase its binding affinity for the MMP2 gene promoter. In VSMCs stimulated with AngII or nicotine, we found an increased DNA affinity of AP-2α, as detected by the electrophoretic mobility shift assay (EMSA), and increased transcriptional activity of AP-2α, as assessed using a luciferase reporter gene (Fig. 5c-f) . Inhibition of AMPK-α2 by either siRNA-mediated knockdown or compound C markedly suppressed AngII-or nicotineinduced AP-2α activation (Fig. 5c-e) . Moreover, metformin increased and AMPK-α2 siRNA decreased the DNA binding affinity of AP-2α (Fig. 5c) .
We next investigated whether AP-2α binds to the MMP2 gene promoter in human VSMCs using chromatin immunoprecipitation (ChIP) analyses. In human VSMCs, the MMP2 gene promoter was positively amplified in samples from AngII-treated cells after immunoprecipitation with primary antibody to AP-2α but not with control immunoglobulin G (IgG), and compound C attenuated this binding (Fig. 5g) . We observed similar effects in nicotine-treated human VSMCs (Fig. 5h,i) . Taken together, these data indicate that AMPK-α2 mediates nicotine-and AngII-induced AP-2α activation.
Nicotine and AngII promote the interaction of AMPK-a2 and AP-2a As AP-2α is located in the nucleus, we determined whether AMPK-α1 and AMPK-α2 were also nuclear localized. Nicotine or AngII treatment of human VSMCs induced nuclear translocation of AMPK-α2 but not AMPK-α1, as assessed by a western blot analysis of separated cytoplasmic and nuclear fractions (Fig. 6a) . Treatment of the cells with compound C inhibited the nicotine-or AngII-promoted AMPK-α2 nuclear translocation. 
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We confirmed the interaction of AMPK-α2 and AP-2α after treatment with either nicotine or AngII by immunoprecipitation experiments. Binding of AMPK-α2 to AP-2α was evident in immunoprecipitates pulled down by antibodies specific to either AP-2α or AMPK-α2 (Fig. 6b) . However, we did not detect binding between AMPK-α1 and AP-2α (Fig. 6b) . We further verified the nuclear translocation of AMPK-α2 and the colocalization of AMPK-α2 and AP-2α using immunofluorescence experiments (Supplementary Fig. 8) . We also detected the interaction of AMPK-α2 and AP-2α using in vitro co-incubation and pulldown experiments (Fig. 6c) . Together, these data suggest that AMPK-α2 directly affects AP-2α activity through a protein-protein interaction.
AMPK increases the phosphorylation of AP-2a at Ser219
Post-translational modifications of AP-2α, including serine phosphorylation, are known to regulate its transcriptional activity 31 . As AMPK is a threonine/serine protein kinase, we reasoned that AMPK might directly phosphorylate AP-2α. Treatment of human VSMCs with either AngII or nicotine resulted in an increase in the level of serine phosphorylation of AP-2α (Fig. 6d) . Conversely, inhibition of AMPK by compound C markedly inhibited AngII-or nicotine-induced AP-2α serine phosphorylation (Fig. 6d) . Moreover, AMPK-α2, but not a dominant-negative version of AMPK-α2, could phosphorylate recombinant AP-2α protein in an in vitro kinase assay, as detected by 32 P-ATP autoradiography, indicating that AP-2α is a direct target of AMPK-α2 (Fig. 6e) .
We next determined which serine residue(s) in the AP-2α protein are phosphorylated by AMPK-α2. In comparison with an optimal AMPK substrate motif 32 , an analysis of AP-2α revealed potential AMPK target motifs at Ser181, Ser219, Ser233, Ser252 and Ser320 in the regulatory and helix-span-helix domains ( Supplementary  Fig. 9a-c) , which are similar to the target motifs in previously identified AMPK substrates [33] [34] [35] . We tested the ability of AMPK-α2 to carry out in vitro phosphorylation of peptides spanning residues 176-185, 214-223, 228-237, 247-256 or 315-324 of AP-2α. A canonical target sequence, the 'SAMS' sequence, was used as a positive control. Only the peptide spanning residues 214-223 of AP-2α was phosphorylated Pro-MMP2, AP-2α, AMPK-α2 and GAPDH proteins were detected by immunoblotting, and MMP2 activity in culture medium was detected by zymography. *P < 0.05 compared to vehicle, # P < 0.05 compared to nicotine alone. (b) Cultured human VSMCs transfected with control siRNA or AP-2α siRNA were untreated (con) or were treated with AngII. Pro-MMP2, AP-2α and GAPDH proteins were detected by immunoblotting, MMP2 and GAPDH mRNA were detected by RT-PCR, and MMP2 activity in culture medium was detected by zymography. *P < 0.05 compared to control siRNA, # P < 0.05 compared to control siRNA plus AngII. (c) Cultured human VSMCs transfected with control siRNA or AMPK-α2 siRNA were either untreated or were treated with AngII or metformin (Met). The DNA binding affinity of AP-2α was determined by EMSA running on nuclear extracts (top) and was quantitated (bottom). The negative control (-) was biotin-labeled DNA probe without extract, and the positive control (+) was biotin-labeled DNA probe with nuclear extract provided by the kit. AMPK-α2 and GAPDH protein were detected by immunoblotting (middle). *P < 0.05 compared to control siRNA, # P < 0.05 compared to control siRNA plus metformin or AngII. (d-i) Cultured human VSMCs preincubated with or without compound C (comp C) were either untreated or treated with vehicle, nicotine or AngII, as indicated. AP-2α activity was detected by EMSA (d,e) or by a luciferase reporter assay (f); binding of AP-2α to the MMP2 gene promoter was detected by ChIP analysis (g,h), and quantitative data from the ChIP analysis is shown in i. *P < 0.05 compared to control or vehicle, # P < 0.05 compared to AngII or nicotine alone (d,e). In f and i, *P < 0.05 compared to control without compound C, # P < 0.05 compared to AngII alone, $ P < 0.05 compared to nicotine alone. For the ChIP analysis shown in g, the positive control was 10% of the total chromatin without immunoprecipitation (lanes 1-4, input); the negative control was chromatin immunoprecipitated with IgG and amplified with MMP2 promoter primers (lanes 5-8), and AP-2α−specific antibody was used to detect the binding of AP-2α to the MMP2 promoter (lanes 9-12). The expected PCR product is 200 bp in size. n = 3 independent experiments for all quantitative data. The P values in a, f and i were obtained by one-way ANOVA plus a post hoc analysis using a Bonferroni test. The error bars in a-f and i are s.e.m.
npg by AMPK-α2 protein (Fig. 6f) . Furthermore, mutation of serine to alanine at Ser6 of the SAMS peptide or at Ser219 of the AP-2α peptide abolished AMPK-α2-induced phosphorylation (Fig. 6g) .
To confirm Ser219 of AP-2α as the phosphorylation target of AMPK-α2, we generated five site-directed mutant constructs of AP-2α (S181A, S219A, S233A, S252A and S320A). In HEK293 cells transfected with WT AP-2α, treatment with AICAR, which induces phosphorylation of AMPK at Thr172, markedly increased AP-2α serine phosphorylation (Fig. 6h) . Among the AP-2α mutant constructs, AICAR-induced AP-2α serine phosphorylation was abolished only in cells transfected with the AP-2α S219A mutant (Fig. 6h) , confirming Ser219 as the target of AMPK-induced AP-2α serine phosphorylation.
We next tested whether Ser219 phosphorylation of AP-2α affects AP-2α activity and function. Transfection of human VSMCs with the AP-2α S219A mutant markedly abrogated AngII-or nicotine-induced upregulation of MMP2 expression and activity, AP-2α DNA binding affinity and AP-2α binding to the MMP2 gene promoter (Supplementary Fig. 10a-c) . These results suggest that Ser219 phosphorylation of AP-2α by AMPK-α2 promotes its binding to the MMP2 promoter, resulting in aberrant MMP2 expression.
AMPK-a2 activation in human AAA and in smokers
To test the relevance of our findings in humans, we examined AMPK-α2 activity, AMPK Thr172 phosphorylation and ACC Ser79 phosphorylation in human AAA tissue. Aortic tissue of patients with AAA showed higher levels of AMPK-α2 activity, AMPK Thr172 phosphorylation and ACC Ser79 phosphorylation than did samples from control patients without AAA (Supplementary Fig. 11a,b) .
To address whether cigarette smoking alters AMPK activity, we assessed AMPK-α2 activity, AMPK Thr172 phosphorylation and npg ACC Ser79 phosphorylation in the blood of both active smokers and nonsmokers. In active smokers, the levels of AMPK-α2 activity, AMPK Thr172 phosphorylation and ACC Ser79 phosphorylation were higher than those in nonsmokers ( Supplementary Fig. 11c,d) , implying that smoking activates AMPK-α2 in humans.
DISCUSSION
Here we show that nicotine-or AngII-derived ROS triggers AMPK-α2 phosphorylation and subsequent nuclear translocation; AMPK-α2 then binds to and phosphorylates AP-2α at Ser219, resulting in aberrant expression of MMP2 and consequent extracellular matrix degradation (Supplementary Fig. 12 ). This mechanism not only provides a causal link between nicotine and AAA but also explains how proinflammatory factors such as ROS promote AAA formation. We found that activation of AMPK-α2 by nicotine or AngII triggered AAA formation in Apoe −/− mice, such that AMPK-α2 deficiency had a marked protective effect. These results might help explain the clinical observation that diabetes is negatively associated with AAA formation 36 , as hyperglycemia suppresses AMPK activity 37, 38 ; conversely, insulin treatment, which lowers blood glucose concentrations, promotes aortic diameter enlargement 39, 40 .
We also found that AP-2α is a direct substrate for phosphorylation by AMPK-α2 at Ser219. AP-2α is also phosphorylated by protein kinase A at Ser233 (ref. 31) and by protein kinase D at both Ser252 and Ser320 (ref. 41) . AP-2α is crucial for mouse embryonic development, and mice lacking AP-2α die at birth 29 . In light of our findings, loss of MMP2 activity in AP-2α-deficient mice may be one of the factors contributing to the embryonic lethality of these mice.
After the acceptance of this paper, a recent publication reported that nicotine accelerates elastase-or AngII-stimulated AAA growth in mice 42 . The results from this study strongly support our findings that VSMC is a key target of nicotine in the initiation and progression of AAA. Moreover, we found that nicotine administration alone can trigger AAA formation and progression in mice. Our results are in line with earlier reports that nicotine, at concentrations relevant to those found in smokers, leads to increased levels of ROS and to AMPK activation in adipocytes 43 , as well as with similar findings on the effects of AngII in VSMCs. Thus, our study extends these observations by showing that AMPK activation might be detrimental in the initiation and progression of AAA, contradicting the idea that AMPK activation is uniformly beneficial in cardiovascular diseases. For example, AMPK-α2 deficiency has been reported to cause accelerated atherosclerosis 44 , and pharmacological activation of AMPK has been shown to attenuate wire-injury-induced vascular remodeling by inhibiting VSMC proliferation 13, 14 . Although atherosclerosis, restenosis and AAA are associated with vascular inflammation and have many of the same predisposing risk factors, there are key differences among these conditions. For example, early atherosclerosis is primarily characterized by foam cell accumulation in the intima, a process that is mediated by proinflammatory factors. In contrast, AAA involves the degradation of the tunica media, in which enhanced activation of the proteolytic system, such as MMPs, has a crucial role 45 . Reduced VSMC proliferation has been found within fragmented media in human AAA biopsy specimens 46 , and the inhibitory effects of AMPK activation on VSMC proliferation might accentuate the development of AAA. This is in contrast to the situation in atherosclerosis and restenosis, in which VSMC proliferation contributes to vascular remodeling 14 . The authors of a recent review 47 concluded that a plurality of studies indicate an independent effect of medications on aneurysms and atherosclerosis in animal models, further suggesting distinct pathogenic mechanisms.
Although both AngII and nicotine promoted AAA formation in Apoe −/− mice through a ROS-AMPK-α2-AP-2α-MMP2 pathway in VSMCs, the incidence and size of the aneurysms induced by AngII was markedly greater than those induced by nicotine for reasons that are unclear. Nicotine might cause a lower level of ROS generation than AngII does. Moreover, AngII has been reported to promote AAA through multiple mechanisms involving transforming growth factor β (TGF-β) and other growth factors 23, 48 . Notably, MMP2 can promote the transcriptional activation of these growth factors as a group, and MMP2 can also interact with TGF-β relating to the processing of MMP2 activation 49 . Whether these pathways also contribute to nicotine-induced AAA warrants further investigation.
The results presented here have established a causal effect of nicotine on AAA in vivo, identifying nicotine as an active agent in smoketriggered AAA. One common approach to the cessation of smoking is nicotine supplementation, such as with gum or patches. The rapid absorption of nicotine can increase plasma nicotine concentrations to as high as 5 × 10 −7 M within 15 min (ref. 50 ), a concentration that, based on our findings, might increase AAA formation. Thus, we suggest that nicotine supplementation be cautiously reconsidered and that the duration of nicotine supplementation be minimized in populations with advanced age.
METHODS
Methods and any associated references are available in the online version of the paper.
Detection of ROS by HPLC. ROS production in mice aortas was detected using the fluorescent probe DHE by HPLC as described previously 27 . DHE fluoresence intensity in Apoe −/− mice aorta infused with saline or vehicle was set as 100%.
Statistical analyses.
Quantitative results are expressed as mean ± s.e.m. Comparisons of parameters between two groups were made by t test. Comparisons of parameters among more than two groups were made by oneway analysis of variance, and comparisons of different parameters between each group were made by a post hoc analysis using a Bonferroni test. A χ 2 test was applied to the comparisons of AAA incidence and survival rate. Statistical significance was evaluated with GraphPad Prism4. A value of P < 0.05 was considered to be statistically significant.
